https://www.selleckchem.com/products/cx-5461.html
h patients without germline BRCA mutation, patients with germline BRCA mutation could benefit more from PARP inhibitors. In clinical setting, hematological toxicity associated with PARP inhibitors should be monitored regularly. The aim of this study was to establish a nomogram model for predicting the risk of short-term recurrence in glioma patients. The clinical data of recurrent glioma patients were summarized and analyzed in this study. Univariate and multivariate logistic regression analyses were performed to analyze the correlation